Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allarity Therapeutics ( (ALLR) ) just unveiled an announcement.
Allarity Therapeutics said it will begin using a new corporate presentation with investors, analysts and other audiences starting May 11, 2026, outlining its DRP companion diagnostics platform and the clinical progress of its lead asset stenoparib in ovarian cancer and small cell lung cancer. On May 8, 2026, the company also reported that CEO Thomas Jensen has been invited to speak at Precision Medicine Forum Europe 2026 in Stockholm on May 11–12, underscoring Allarity’s efforts to raise its profile in precision oncology and attract stakeholder attention to its biomarker-driven development strategy.
The most recent analyst rating on (ALLR) stock is a Buy with a $9.75 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Neutral.
Overall score is held back primarily by weak financial performance (minimal revenue and multi-year cash burn) and a negative-earnings valuation profile. Technicals are comparatively supportive with price above key moving averages and positive MACD, but the structured note financing introduces added constraint risk despite improving liquidity.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc., listed on Nasdaq as ALLR, is a clinical-stage oncology company built around its proprietary Drug Response Predictor (DRP) gene expression platform, which is designed to match cancer drugs with patients most likely to benefit. The company holds exclusive global rights to stenoparib, a dual PARP and WNT pathway inhibitor in Phase 2 trials for platinum-resistant ovarian cancer and relapsed small cell lung cancer, and is focused on revitalizing former big pharma therapeutics using DRP-based companion diagnostics to improve treatment outcomes.
Average Trading Volume: 166,389
Technical Sentiment Signal: Hold
Current Market Cap: $23.73M
For a thorough assessment of ALLR stock, go to TipRanks’ Stock Analysis page.